Investigations

GRABAR LAW OFFICE INVESTIGATES POTENTIAL SHAREHOLDER ACTION ON BEHALF OF SHAREHOLDERS OF APYX MEDICAL CORPORATION (NASDAQ: APYX)

A federal judge found that a securities fraud complaint “sufficiently pleads a strong inference of [wrongdoing] such that a reasonable person would infer that Apyx perpetrated a fraud." That suit accused Apyx, formerly known as Bovie Medical Corp., of keeping secret the outcome of an investigational device exemption clinical study of J-Plasma, a skin-tightening product it had hoped would receive U.S. Food and Drug Administration regulatory clearance. While on August 1, 2018, the company claimed that "results from the dermal resurfacing U.S. IDE clinical study will support our 510(k) submission to the FDA," on April 1, 2019, the company announced it was withdrawing its FDA application for J-Plasma.  These failures in corporate governance caused a precipitous drop in Apyx’s stock price and great reputational harm to the company. 

Current Apyx shareholders who have held shares of the Company’s stock since at least August 1, 2018 have standing to seek corporate governance reforms, the return of funds back to company coffers and potentially a court approved incentive award if appropriate at no cost. $APYX

If you would like to learn more at no cost to you, fill out the form provided or contact us at jgrabar@grabarlaw.com or call 267-507-6085. 

Contact Us

Please enter your name.
Please enter a valid phone number.
Please enter a message.

Standard Derivative Form Retainer

Standard Form Derivative Retainer Letter - No Cost
  • Join This Action

  • Alternatively, you may upload your transactions using the upload button below or email them to jgrabar@grabarlaw.com. *

  • Drop files here or
    Max. file size: 100 MB.
    • Signed pursuant to California Civil Code Section 1633.1, et seq. and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.
    • Date of signing: *

    • MM slash DD slash YYYY
    • This field is for validation purposes and should be left unchanged.